• Media
    • Press Releases
    • Archives
    • Media Inquiries
    • In the News
  • Join Us
    • Overview
    • Life at Tris
    • Our Culture
    • Diversity & Belonging
    • Current Opportunities
  • Connect
    • Contact Us
    • Join our Mailing List
Tris PharmaTris Pharma
  • Who We Are
    • Tris at a Glance
    • Leadership
    • Scientific Advisors
    • Patient Advocacy
    • Partnerships
    • Our Culture
    • Diversity & Belonging
    • Sustainability
    • Compliance
  • Medicines
  • Innovation
    • Overview
    • ADHD
    • Pain
    • Addiction
    • Technologies
  • Pipeline
    • Overview
    • ADHD Pipeline
    • Pain Pipeline
    • Other CNS Disorders
    • Clinical Publications
  • Who We Are
    • Tris at a Glance
    • Leadership
    • Scientific Advisors
    • Patient Advocacy
    • Partnerships
    • Our Culture
    • Diversity & Belonging
    • Sustainability
    • Compliance
  • Medicines
  • Innovation
    • Overview
    • ADHD
    • Pain
    • Addiction
    • Technologies
  • Pipeline
    • Overview
    • ADHD Pipeline
    • Pain Pipeline
    • Other CNS Disorders
    • Clinical Publications
  • Media
    • Press Releases
    • Archives
    • Media Inquiries
    • In the News
  • Join Us
    • Overview
    • Life at Tris
    • Our Culture
    • Diversity & Belonging
    • Current Opportunities
  • Connect
    • Contact Us
    • Join our Mailing List

Media

  • Press Releases
  • Archives
  • Media Inquiries
  • In the News

Press Releases

FEATURED PRESS RELEASE

ODD-PR-Website-Image

November 16, 2026

Tris Pharma Named a BioSpace 2027 Best Places to Work Winner

November 9, 2026

Adneuris Therapeutics Reaches Key Regulatory Milestone with FDA Submission of New Drug Application for Cebranopadol in Moderate-to-Severe Acute Pain

October 14, 2026

Tris Pharma Earns 2026 Great Place To Work Certification™

September 14, 2026

Tris Pharma Introduces New 30-Count Bottle Size for QuilliChew ER® (methylphenidate HCl) Extended-Release Chewable Tablets for Attention Deficit Hyperactivity Disorder (ADHD)

September 3, 2026

Adneuris Therapeutics to Present at PAINWeek 2026
  • Who We Are
    • Tris at a Glance
    • Leadership
    • Scientific Advisors
    • Patient Advocacy
    • Partnerships
    • Our Culture
    • Diversity & Belonging
    • Sustainability
    • Compliance
  • Medicines
    • ADHD Products
  • Innovation
    • Overview
    • ADHD
    • Pain
    • Addiction
    • Technologies
  • Pipeline
    • Overview
    • ADHD Pipeline
    • Pain Pipeline
    • Other CNS Disorders
    • Clinical Publications
  • Join Us
    • Overview
    • Life at Tris
    • Our Culture
    • Diversity & Belonging
    • Current Opportunities
  • Media
    • Press Releases
    • Archives
    • Media Inquiries
    • In the News
  • Connect
    • Contact Us
    • Join our Mailing List
Site Logo
  • Who We Are
  • ADHD Products
  • Innovation
  • Pipeline
  • Media
  • Join Us
  • Connect

Tris Pharma logo

LinkedIn

instagram

twitter

facebook

Great place to work

Tris Pharma, Inc.
2031 US Highway 130
Monmouth Junction, NJ 08852

Telephone: (732) 940-2800

  • Privacy Policy
  • Terms and Conditions
  • Financial Conflict of Interest
  • Social
  • Cookies
  • Accessibility Statement

© Copyright 2026 Tris Pharma, Inc.